SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 1st, 2024 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 28, 2024, between NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD.Common Share Purchase Warrant • July 1st, 2024 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations
THIS COMMON SHARE PURCHASE WARRANT, issued in the form of uncertificated securities (Wertrechte) pursuant to article 973c of the Swiss Code of Obligations (the “Warrant”), certifies that, for value received, [_______________], or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July 2, 2029 (the “Termination Date”) but not thereafter, to subscribe for and/or purchase from NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the “Company”), up to [________] Common Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). The Company may issue the Warrant Shares from its Treasury Shares and/or conditional capi
SERIES A PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD.Security Agreement • July 1st, 2024 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations
THIS SERIES A PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT, issued in the form of uncertificated securities (Wertrechte) pursuant to article 973c of the Swiss Code of Obligations (the “Warrant”), certifies that, for value received, [_______________], or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June 28, 2029 (the “Termination Date”) but not thereafter, to subscribe for and/or purchase from NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the “Company”), up to [________] Common Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). The Company may issue the Warrant Shares from its Treasury Shar
SERIES B PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD.Series B Placement • July 1st, 2024 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations
THIS SERIES B PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT, issued in the form of uncertificated securities (Wertrechte) pursuant to article 973c of the Swiss Code of Obligations (the “Warrant”), certifies that, for value received, [_______________], or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that the Company (i) obtains approval from its shareholders to increase the number of its authorized common shares to an amount sufficient to allow the Company to issue the Warrant Shares (as defined below) hereunder together with any and all common shares underlying any other Series B Placement Agent Common Share Purchase Warrants issued on the date hereof and (ii) effects such increase (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June 28, 2029 (the “Termination Date”) but not thereafter, to subscribe for and/or purchase from N
